IMCD (OTCMKTS:IMCDY – Get Free Report) was the target of a large increase in short interest in October. As of October 15th, there was short interest totaling 1,389 shares, an increase of 481.2% from the September 30th total of 239 shares. Based on an average trading volume of 17,776 shares, the short-interest ratio is currently 0.1 days.
IMCD Trading Down 0.9%
Shares of IMCD stock opened at $55.95 on Tuesday. The stock has a 50-day simple moving average of $55.83 and a 200-day simple moving average of $51.71. IMCD has a 52-week low of $39.76 and a 52-week high of $61.56.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IMCD in a report on Thursday, July 30th. UBS Group raised IMCD to a “buy” rating in a research report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, IMCD presently has a consensus rating of “Hold”.
View Our Latest Stock Report on IMCDY
About IMCD
IMCD N.V. is a global distributor and formulator of specialty chemicals and food and pharmaceutical ingredients. The company connects manufacturers with customers across a range of industries, including coatings and construction, personal care, pharmaceuticals, food and nutrition, lubricants, advanced materials, and industrial solutions.
In addition to distributing products, IMCD provides technical support, application development, formulation assistance, regulatory guidance, and supply-chain services.
Featured Articles
- Five stocks we like better than IMCD
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for IMCD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMCD and related companies with MarketBeat.com's FREE daily email newsletter.
